Opinion|Videos|October 7, 2024
Inclusion of Chemotherapy and Impact on Outcomes From the ARASENS Trial
Author(s)Fred Saad, CQ, MD, FRCS, FCAHS
Key Takeaways
- Chemotherapy, particularly docetaxel, significantly influences the adverse event profile, with common side effects including neutropenia, fatigue, and diarrhea.
- The ARASENS trial findings align with previous studies, confirming the consistency of observed adverse effects with clinical practice.
Fred Saad, CQ, MD, FRCS, FCAHS, discusses how the inclusion of chemotherapy, particularly docetaxel, in combination therapies for metastatic prostate cancer alters the adverse event profile, noting that while the ARASENS trial found adverse effects to be largely consistent with previous docetaxel studies, they consider whether this aligns with observations in clinical practice.
Advertisement
Video Content above is prompted by the following:
- How does inclusion of chemotherapy affect the adverse event profile? In the ARASENS trial (NCT02799602), authors concluded that many of the adverse effects were consistent with those observed in previous studies with docetaxel. Is this consistent with what you see in clinical practice?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves first-line Zenflow system for the treatment of BPH
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5
